Showing 6761-6770 of 7862 results for "".
- Skin Cancer Risk Varies Based on Organ Transplant Patients' Skin Tonehttps://practicaldermatology.com/news/skin-cancer-risk-varies-based-on-organ-transplant-patients-skin-tone/2457673/Dermatologists must know how to evaluate organ transplant patients’ unique risk factors for skin cancer and counsel these patients accordingly. “Individuals who receive organ transplants need to take immunosuppressive medications for the rest of their lives, and this makes it
- AAD: Research Shows Free Skin Cancer Screenings Can Help Save Liveshttps://practicaldermatology.com/news/aad-research-shows-free-skin-cancer-screenings-can-help-save-lives/2457675/Data indicates that American Academy of Dermatology’s (AAD's) SPOTme program serves an important need. While skin cancer can be deadly, it is also highly treatable when detected early. In fact, melanoma, the deadliest form of skin cancer, has a five-year survival rate of 95 percen
- Pulse Biosciences: First Patients Treated in Study of Sebaceous Hyperplasia Lesionshttps://practicaldermatology.com/news/pulse-biosciences-first-patients-treated-in-study-of-sebaceous-hyperplasia-lesions/2457682/Pulse Biosciences, Inc. says the first patients have been treated in its multi-center study to evaluate the safety and efficacy of its Nano-Pulse Stimulation (NPS) technology for eliminating Sebaceous Hyperplasia (SH). SH is an unsightly benign skin lesion that typically appears on facial skin an
- Can Turning Off a Mutation Causing Wrinkling and Hair Loss Reverse the Processes? New Mouse Model Says Yeshttps://practicaldermatology.com/news/can-turning-off-a-mutation-causing-wrinkling-and-hair-loss-reverse-the-processes-new-mouse-model-says-yes/2457680/A new mouse model may one day allow scientists to reverse age-associated wrinkles and hair loss. When a mutation leading to mitochondrial dysfunction is induced, the mouse develops wrinkled skin and extensive, visible hair loss in a matter of weeks, but when the mitochondrial function is
- Breaking News: Galderma Skinpact Awards Deadline Extended!https://practicaldermatology.com/news/breaking-news-galderma-skinpact-awards-deadline-extended/2457683/The new deadline for the Galderma Skinpact Awards is July 31, 2018. The awards are a social responsibility program by Galderma International in partnership with the Canadian Dermatology Association, and the Women's Dermatolo
- Trevi Therapeutics Appoints Yann Mazabraud as Chief Commercial Officerhttps://practicaldermatology.com/news/trevi-therapeutics-appoints-yann-mazabraud-as-chief-commercial-officer/2457685/Trevi Therapeutics, Inc. has named Yann Mazabraud as its Chief Commercial Officer and Head of International. Mr. Mazabraud will join Trevi’s senior management team and be responsible for overseeing Trevi’s commercial strategy and international operations.
- Game On: Head-to-head Trials to Enhance Competition in PsO Markethttps://practicaldermatology.com/news/head-to-head-trials-to-enhance-competition-in-pso-market/2457684/An increase in head-to-head trials will enhance the competition within the psoriasis market, according to
- BioPharmX: FDA Grants CARC Waiver; Post-Hoc Analysis for BPX-01 Completehttps://practicaldermatology.com/news/biopharmx-fda-grants-carc-waiver-post-hoc-analysis-for-bpx-01-complete/2457686/The FDA has waived its requirement for a dermal carcinogenicity study for BPX-01 from BioPharmX Corporation, eliminating several years of non-clinical research normally required for FDA review. BPX-01, a novel topical gel formulation of minocycline for the treatment of inflammatory
- AD Takes Big Toll on QOLhttps://practicaldermatology.com/news/ad-takes-a-big-toll-on-qol/2457691/Itch, dryness and other eczema symptoms negatively affect quality of life, according to a new study published in the Annals of Allergy, Asthma and Immunology. Of 602 adults with eczema, symptoms that were the bigg
- Sensus Healthcare Forms Strategic Agreement with SkinCure Oncologyhttps://practicaldermatology.com/news/sensus-healthcare-forms-strategic-agreement-with-skincure-oncology/2457697/Sensus Healthcare, Inc., which specializes in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), formed a strategic agreement focused on marketing the SRT-100 Vision with SkinCure Oncology, a leading turnkey provider